This week's BioCentury has an interesting analysis of European biotech - both public and private. A tidbit worth amplifying: (All figures from BioCentury.)
-Good news: the number of private European biotech companies with clinical activities is higher than ever, up 8% in 2011 to 235 companies. These companies are likely to need total financing to support clinical development of $5.7B through 2014.
-Europe's private biotechs raised $1.2B in new capital in 2011.
Bad news: given the demand for funding to support onward development, and the likely supply of capital, there's an approximately $1B funding gap between now and 2014. In addition, public European biotech's have an annual capital appetite of approximately $1.8B.
European biotech's tend to have more readily available government support/financing, but given the financial crisis in Europe, I'd say that it's time to get your checkbooks out, Big Pharma. (At least it should be a buyers market.)
A more dim view might be that there's going to be billions worth of headcount reductions in Europe's biotech's.
Showing posts with label Europe. Show all posts
Showing posts with label Europe. Show all posts
Monday, May 21, 2012
Subscribe to:
Comments (Atom)
